首页/数据集/Subjects with TEAEs by SOC and PT, reported ≥5% in any group.

Subjects with TEAEs by SOC and PT, reported ≥5% in any group.

Figshare2021-09-23 更新2026-04-28 收录

药物安全性评估

临床试验不良事件

数据链接：

https://figshare.com/articles/dataset/Subjects_with_TEAEs_by_SOC_and_PT_reported_5_in_any_group_/16672995 数据链接链接失效反馈

官方服务：

资源简介：

Subjects with TEAEs by SOC and PT, reported ≥5% in any group.

应用场景：

创建时间：

2021-09-23

特应性皮炎

药物安全性评估

A phase 2, double-blind, placebo-controlled trial evaluated apremilast efficacy, safety, and pharmacodynamics in adults with moderate to severe atopic dermatitis (AD). Overall design: Patients were ra

NIAID Data Ecosystem100

Prior and Concomitant Medications and Systemic Antimicrobials in Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants <750 Grams Birth Weight

新生儿抗真菌预防

药物安全性评估

Prior and Concomitant Medications and Systemic Antimicrobials Dataset Study Description This was a prospective, randomized, double-blind, multi-center, efficacy study comparing fluconazole prophylaxis

NIAID Data Ecosystem50

Efficacy, safety, and ARIA risk of anti–β-amyloid antibodies in early Alzheimer’s disease: a systematic review, meta-analysis, and meta-regression

阿尔茨海默病药物

药物安全性评估

Alzheimer’s disease (AD) is the most prevalent cause of dementia and has been closely linked to βSupplemental data for this article can be accessed online at ht tps://doi.org/-amyloid accumulation. Ho

NIAID Data Ecosystem40

Number (%) of Subjects with Adverse Events During Days 1 to 28.

疫苗安全性监测

临床试验不良事件

Note: *Determined by the investigator to be possibly or probably related to the study vaccine.

NIAID Data Ecosystem50

Number of Grade 2–4* adverse events reported.

HIV药物安全性监测

临床试验不良事件

Number of Grade 2–4* adverse events reported.

Figshare2015-12-02 更新50